Compare SLP & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLP | DCTH |
|---|---|---|
| Founded | 1996 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.9M | 363.5M |
| IPO Year | 1996 | 2015 |
| Metric | SLP | DCTH |
|---|---|---|
| Price | $16.57 | $11.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $24.00 | $22.00 |
| AVG Volume (30 Days) | ★ 385.1K | 306.5K |
| Earning Date | 04-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $59,577,000.00 | N/A |
| Revenue This Year | $3.80 | $24.54 |
| Revenue Next Year | $5.90 | $33.15 |
| P/E Ratio | ★ $61.60 | $161.57 |
| Revenue Growth | ★ 10.52 | N/A |
| 52 Week Low | $11.09 | $8.12 |
| 52 Week High | $34.01 | $18.23 |
| Indicator | SLP | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 72.88 | 61.37 |
| Support Level | $16.26 | $10.17 |
| Resistance Level | $19.29 | $11.99 |
| Average True Range (ATR) | 0.86 | 0.52 |
| MACD | 0.15 | 0.04 |
| Stochastic Oscillator | 79.56 | 63.06 |
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.